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DISCUSSION
Dr John F. Eidt (Little Rock, Ark) I want to thank Mark
G. Davies and the other authors for providing me with a copy
of the manuscript well in advance of the meeting. There is a lot
of information and I commend the authors for a thorough
analysis.
The premise of the current manuscript is that runoff might
have a different effect on the outcome from percutaneous inter-
vention than following conventional surgery. Numerous surgical
authors have tried to correlate the anatomic and/or physiologic
runoff with the results of vascular reconstruction for decades with
varying degrees of success.
In short, runoff matters. In the present study, runoff scores
correlated with most measurable outcomes including limb salvage,
patency, recurrence of symptoms and need for target lesion revas-
cularization. Runoff is really a marker for the severity of systemic
disease as demonstrated by the fact that overall survival in this study
was related to the runoff score.
It would be tempting to conclude that these results support
the preferential use of percutaneous options in patients with critical
limb ischemia (CLI) with better runoff. The overall limb salvage
was somewhat less than 50% at 5 years. Is this the best we can do?
Since this is a highly-selected group of patients without a compar-
ison group of any kind, I would caution that it is hazardous to use
these data to support any particular treatment option.
I have four questions.
The first question is related to your terminology. Is Target
Lesion Revascularization (TLR) an appropriate measure of efficacy
in patients with CLI? Does TLR include amputations?
Second, there was a conspicuous absence of physiologic data
such as ankle brachial indices (ABIs) to support the efficacy of
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treatment. Do you have any non-invasive data to corroborate the
initial clinical classification and, more importantly, the effect of
treatment?
Third, I have had the unfortunate experience of losing runoff
vessels as the result of proximal intervention. I noticed that embo-
lectomy or thrombolysis was necessary in 8-14% of your patients.
Did you observe examples in which the percutaneous intervention
resulted in a deterioration of the anatomic runoff score?
Finally, our goal is to select the best treatment for a single
patient. In your series, only about 10% of patients ever had surgical
intervention. Do you have any idea how many patients were
treated surgically at your institution for similar indications during
the same time period? How were patients selected for percutane-
ous treatment? Should more of these patients been referred for
definitive surgical reconstruction?
Dr Mark G. Davies. There are several definitions of target
lesion revascularization. The definition we used is a composite
measure of success used in several recent papers. Freedom from
target lesion revascularization (TLR) was defined as the absence of
clinically driven repeat revascularization of the target lesion (endo-
vascular therapy for symptomatic stenosis) or the need for surgical
bypass grafting or amputation due to re-occlusion of the target
lesion as diagnosed by arteriography or duplex scan. We also
included the patency and limb salvage rates with the different types
of amputations so that one can differentiate out the reasons for
TLR. With regard to the non-invasives studies and post procedure
ABI improvement, the high incidence of diabetes in this study
group meant there were many patients with noncompressive ves-
sels (20% who do not have meaningful ABI data). Many did not
get toe pressure measurements. Since this data is garnered from the
experience of a multidisciplinary service line and not a primary
vascular surgery service, there is a fraction of patients that had no
initial non-invasive data. Of those that do, 80% of them did have a
hemodynamic improvement.With regard to loss of runoff, we have
about a 1% embolization rate, which necessitated embolectomy.
We did go through a period early in our experience, where we
would try to lyze distal emboli, but it is generally plaque; we now
go straight to embolectomy and not delay 24 hrs to see if lysis will
work. The higher use of thrombolysis is related to in situ throm-
bosis and in that case, we would use thrombolysis for a period of
one to two days. Previous reports, however, show that use of
thrombolysis during an SFA intervention is associated with a
decrease in cumulative patency. The main message of this paper is
that while endoluminal intervention is safe and technically success-
ful it may not be correct primary modality in the fit patient with
poor runoff. The physician undertaking the procedure needs to
more critically analyze the chances for success and consider referral
for open surgery. The second point to emphasize is that runoff
matters irrespective of the treatment modality used and that ex-
trapolation of results from other organs with regard to runoff is not
applicable in the leg.
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